drugset / Trial / NCT00043420
CPG 7909 in Patients With Cutaneous T-Cell Lymphoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To assess the effect of CPG 7909 Injection on Cutaneous T-cell lymphoma and the safety of CPG 7909 Injection in patients with this cancer.
Timeline
- Start
- 2003-01
- Primary completion
- 2007-03
- Completion
- 2007-03
Publications
- Valipour A, Jager M, Wu P, Schmitt J, Bunch C, Weberschock T. Interventions for mycosis fungoides. Cochrane Database Syst Rev. 2020 Jul 7;7(7):CD008946. doi: 10.1002/14651858.CD008946.pub3.
- Kim YH, Girardi M, Duvic M, Kuzel T, Link BK, Pinter-Brown L, Rook AH. Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. J Am Acad Dermatol. 2010 Dec;63(6):975-83. doi: 10.1016/j.jaad.2009.12.052.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | agatolimod | Oligonucleotide (other) | 0.08 mg/kg | Subcutaneous |
| Subject | agatolimod | Oligonucleotide (other) | 0.16 mg/kg | Subcutaneous |
| Subject | agatolimod | Oligonucleotide (other) | 0.24 mg/kg | Subcutaneous |
| Subject | agatolimod | Oligonucleotide (other) | 0.28 mg/kg | Subcutaneous |
| Subject | agatolimod | Oligonucleotide (other) | 0.32 mg/kg | Subcutaneous |
| Subject | agatolimod | Oligonucleotide (other) | 0.36 mg/kg | Subcutaneous |
| Subject | agatolimod | Oligonucleotide (other) | 10 mg | Subcutaneous |
| Subject | agatolimod | Oligonucleotide (other) | 25 mg | Subcutaneous |